Replies to post #197626 on Biotech Values

[DewDiligence]

Re: ENTA FY4Q15 CC

As regarding to their future pipeline development, there are no indications of potential markets they intend to address.

I do not understand what you mean. For the in-house HCV program, Jay Luly indicated the intention to focus on the market for hard-to-treat patients with DAA-induced RAVs. For the NASH compound, the target market is essentially anyone with NASH.

ENTA's management was evasive answering any question and promising to provide some future clarification.

Only with respect to questions about details of the ABBV collaboration that ENTA is not at liberty to divulge—e.g. the sales thresholds for the five V-Pak/Technivie/Viekirax royalty tiers. (The CC analysts know ENTA will not be able to answer these kinds of questions, but they ask them anyhow.)

It appears they operate like an academia rather than a commercial company.

Again, I disagree. How many academic enterprises are profitable?